Menu

Silencing Surprise

A chromatin remodeler in embryonic stem cells clears the DNA for mRNA transcription while stifling the expression of noncoding transcripts.

Jun 1, 2015
Jenny Rood

BAF BLOCKER: In normal embryonic stem cells (top panel), the chromatin remodeling complex esBAF moves nucleosomes into enhancer-flanking DNA regions (blue) to keep enhancers (red) free of nucleosomes so they can promote transcription of protein-coding genes. When esBAF is absent (lower panel), nucleosomes move out of the flanking regions and into the enhancer, freeing up noncoding RNA transcription that begins in the enhancer and continues into the flanking DNA.© SCOTT LEIGHTON

EDITOR'S CHOICE IN GENETICS & GENOMICS

The paper
S.J. Hainer et al., “Suppression of pervasive noncoding transcription in embryonic stem cells by esBAF,” Genes & Development, 29:362-78, 2015.

To stuff more than six feet of DNA into the nucleus of each cell in our body, the genome winds tightly around a core of eight histone proteins, creating structures called nucleosomes that, in turn, are densely packed into chromatin. To transcribe genetic information from DNA to RNA, nucleosomes must be shifted out of the way, a task performed in some cases by the embryonic stem cell chromatin remodeling complex esBAF. This process opens up not just the region of DNA to be transcribed, but promoters and enhancers that encourage transcription.

Recent genome-sequencing work has revealed that enhancer regions not only promote the transcription of protein-coding genes, but can also contain the script for noncoding RNAs. Although noncoding RNAs are a hot topic, how they are regulated isn’t understood, says Toshio Tsukiyama of the University of Washington.

Thomas Fazzio, a former graduate student of Tsukiyama who is now an assistant professor at the University of Massachusetts Medical School, wanted to understand how the positioning of nucleosomes near enhancers might regulate noncoding RNA transcribed from the enhancer region. “We thought it was almost obvious that if BAF is important for keeping the chromatin structure of lots of enhancers open,” it would support the transcription of noncoding RNAs from those genomic stretches as well, he says. Yet when Fazzio and his colleagues sequenced the RNA from esBAF knockdown mouse embryonic stem cells, they found that noncoding RNAs from approximately 57,000 genomic regions were expressed at higher levels than in the control. The effect was not seen in more-differentiated mouse embryonic fibroblasts.

To further explore the unexpected finding, the researchers treated the DNA with an enzyme that only cuts in nucleosome-free regions and sequenced the fragments to determine the nucleosomes’ locations. Enhancer regions of esBAF knockout cells were covered by nucleosomes, but there were far fewer nucleosomes in flanking regions, suggesting that esBAF increases the nucleosome occupancy there. Adding DNA sequences that lock nucleosomes in place at both sides of the enhancer repressed the noncoding transcripts, even without esBAF. “I was really impressed that using mammalian cells they actually...directly show that it is really the nucleosome occupancy that matters for noncoding RNA regulation,” says Tsukiyama, who did not participate in the experiments.

The results point “to the intricacies of how [chromatin remodeling] complexes are used by the cell,” says Swaminathan Venkatesh of the Stowers Institute for Medical Research in Kansas City, Missouri, who was not involved in the study. “A complex that has traditionally been viewed to be involved in activating transcription is actually repressing noncoding transcripts.”

It’s not clear how important the repression of noncoding transcripts is for pluripotency, Fazzio says. There are many long noncoding RNAs implicated in differentiation, says Venkatesh, and “you can imagine that suppressing them in embryonic stem cells is preventing differentiation from taking place.”

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!